Merck earnings top estimates amid solid demand for Keytruda cancer drug

Investing.comOct 31, 2024 12:32 PM

View all comments（0）



Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ongoing sluggishness in sales of its Gardasil vaccine in China.

Earnings for the three months ended on Sept. 30 came in at $3.99 billion, or $1.57 per share, dipping from the year-ago period due to acquisition-related expenses. However, the figure still topped expectations of $1.50, according to LSEG data cited by Reuters.

Underpinning the return were Keytruda sales, which jumped by 17% to $7.43 billion, beating Wall Street forecasts.
However, sales of Gardasil, a treatment for cancers caused by the human papillomavirus, dropped by 11% to a lower-than-projected $2.31 billion. Chief Executive Rob Davis said it was a "demand issue driven by the economy," while there was also some impact on promotional activity linked to concerns around recent campaign in China targeting bribery of doctors, Reuters reported.

Group-wide sales also moved up by 4% to $16.66 billion, above estimates of $16.45 billion.

Meanwhile, the company narrowed its full-year sales forecast, citing a solid growth and new product launches as well as a negative impact from foreign exchange headwinds.

For the 2024 fiscal year, sales are seen at $63.6 billion to $64.1 billion, compared to an earlier range of $63.4 billion to $64.4 billion. Adjusted per-share income is now tipped to come in at $7.72 to %7.77, down from an earlier band of $7.94 to $8.04.

Shares in Merck and Co. were little changed in premarket US trading on Thursday.

(Reuters contributed reporting.)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Today’s Market Recap: Broadcom and Nvidia Lead Tech Gains, Oil Prices Surge, Gold Under Pressure

TradingKey - On July 8, Eastern Time, US stocks showed divergent performance. Escalating conflicts between the US and Iran pushed energy prices back up, fueling market concerns over sticky inflation and the Federal Reserve's policy path, which dragged down the Dow Jones Industrial Average and the S&

NVIDIA (NVDA) Stock Forecast: DeepSeek Building Its Own Chip - Is $197 the Bottom?

Reuters says DeepSeek is building its own AI chip to cut ties with Nvidia. NVDA slipped 2% on the news but still holds $197. The chart has flipped to a long setup. 61 analysts Buy at $301 avg target.

Japan and South Korea Stocks Surge at Open: Nikkei 225 and Kospi Soar Together, SK Hynix and Kioxia Jump 8%, Samsung and SoftBank Follow

Japanese and South Korean stock markets opened higher and continued to rise, with the KOSPI Index and the Nikkei 225 index gaining to varying degrees. SK Hynix and Kioxia surged by approximately 8%, while Samsung Electronics and SoftBank tracked the gains.

US Stocks Close: Dow Plunges 1.09%, Nasdaq Rises Against Trend, Philadelphia Semiconductor Index Gains Over 2%; Trump Announces End of US-Iran Ceasefire Agreement, Some Fed Officials See Need for Rate Hike.

TradingKey - Donald Trump publicly stated that he has no intention of resuming any agreement negotiations with Iran, dampening market trading sentiment. The three major US stock indexes diverged, with the Dow Jones Industrial Average taking a hit, the Nasdaq Composite rising, blue-chip stocks declining, and memory chip stocks rebounding. At the close, the Dow Jones Industrial Average fell 1.09% to 52,348.39 points; the Nasdaq Composite Index rose 0.20% to 25,870.65 points; and the S&P 500 Index fell 0.28% to 7,482.71 points.

FOMC Minutes: Fed Shifts to Neutral Wait-and-See Stance, a Few Officials See Need to Raise Rates, Upside Inflation Risks Become Core Conflict

The Federal Reserve released the minutes of its June 16-17 FOMC monetary policy meeting on July 8. The document shows that the Fed's policy has completely shifted to a neutral, wait-and-see stance, with upside risks to inflation becoming the core contradiction. This FOMC meeting sent a clear signal that the Fed has completely moved away from its previous unilateral rate-cut bias and entered a period of two-way, flexible policy observation. Higher-than-expected inflation stickiness and its broadening scope are the core reasons for this policy shift, while the resilience of employment and growth provides room for flexible policy adjustments. Officials confirmed a further rise in inflation, noting that pressures are no longer confined to exogenous factors such as energy and tariffs. Instead, price increases have spread across a wide range of categories including transportation, airfares, and oil, with service inflation excluding housing showing almost no improvement. In the short term, as shipping through the Strait of Hormuz recovers and the marginal effects of tariffs fade, inflation is expected to decline gradually.

Featured Tools